Immix Biopharma (IMMX) Income from Non-Controlling Interests (2023 - 2026)

Immix Biopharma (IMMX) has 3 years of Income from Non-Controlling Interests data on file, last reported at $69141.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Non-Controlling Interests changed N/A year-over-year to $69141.0; the trailing twelve-month figure through Mar 2026 stood at $56227.0 (changed N/A YoY), and the FY2024 full-year result was -$84987.0, up 49.85% from the prior year.
• Income from Non-Controlling Interests grew to $69141.0 in Q1 2026, from -$12914.0 in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $69141.0 in Q1 2026 to a low of -$72073.0 in Q1 2024.
• A 3-year average of -$26474.3 and a median of -$21996.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
• Peak annual rise in Income from Non-Controlling Interests reached 41.29% in 2024, while the deepest fall reached 292.38% in 2024.
• Tracing IMMX's Income from Non-Controlling Interests over 3 years: stood at -$65862.0 in 2023, then jumped by 80.39% to -$12914.0 in 2024, then jumped by 635.4% to $69141.0 in 2026.
• Business Quant data shows IMMX's Income from Non-Controlling Interests at $69141.0 in Q1 2026, -$12914.0 in Q2 2024, and -$72073.0 in Q1 2024.